Cargando…

Reduction in oral mucositis severity using a topical vasoconstrictor: A case report of three bone marrow transplant patients

BACKGROUND: Grade 3 oral mucositis (OM) is historically observed in >90% of bone marrow transplant patients who received the cyclophosphamide + total body irradiation (CY+TBI) conditioning regimen. It was previously shown that orotopically applied adrenergic vasoconstrictor prevented up to 100% o...

Descripción completa

Detalles Bibliográficos
Autores principales: Graul-Conroy, Amanda, Hoover-Regan, Margo, DeSantes, Kenneth B, Sondel, Paul M, Callander, Natalie S, Longo, Walter L, Fahl, William E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6907163/
https://www.ncbi.nlm.nih.gov/pubmed/31832233
http://dx.doi.org/10.15761/ICST.1000293
_version_ 1783478493499097088
author Graul-Conroy, Amanda
Hoover-Regan, Margo
DeSantes, Kenneth B
Sondel, Paul M
Callander, Natalie S
Longo, Walter L
Fahl, William E
author_facet Graul-Conroy, Amanda
Hoover-Regan, Margo
DeSantes, Kenneth B
Sondel, Paul M
Callander, Natalie S
Longo, Walter L
Fahl, William E
author_sort Graul-Conroy, Amanda
collection PubMed
description BACKGROUND: Grade 3 oral mucositis (OM) is historically observed in >90% of bone marrow transplant patients who received the cyclophosphamide + total body irradiation (CY+TBI) conditioning regimen. It was previously shown that orotopically applied adrenergic vasoconstrictor prevented up to 100% of radiation-induced oral mucositis in two preclinical animal models. METHODS: Adrenergic vasoconstrictor (i.e., phenylephrine in an aqueous-alcohol NG11–1 formulation) was orotopically applied to three patients (ages 24–29) who received the CY+TBI conditioning regimen; they were compared to five matched controls who received no orotopical vasoconstrictor. All patients received the CY+TBI conditioning regimen for acute lymphoblastic leukemia within the University of Wisconsin Adult Bone Marrow Transplant Program. Over the seven-day Cy+TBI conditioning regimen, 20 min before each treatment, either radiation or chemotherapy, vasoconstrictor was applied topically to the oral cavity, and patients then received either 1.5 Gy whole-body radiation or IV cyclophosphamide. RESULTS: OM severity was scored over a three-week period using: i) physican assessments, ii) daily photos of the oral cavity, iii) oral pain and oral function score sheets, and iv) recorded narcotic consumption. Both “Grade 3 OM” duration and “any OM” duration in vasoconstrictor-treated patients were substantially lower than for the five control patients. Though nasogastric tube or total parenteral nutrition were used in 3 out of 5 control patients, there was no use of these supportive care measures in the three vasoconstrictor-treated patients. CONCLUSION: Orotopically applied NG11–1 vasoconstrictor formulation substantially reduced the incidence and severity of “Grade 3” and “any” oral mucositis when compared to matched control patients, all of whom received the same CY+TBI conditioning regimen. The liquid orotopical formulation was easily tolerated by patients both in its ease of use and lack of side effects.
format Online
Article
Text
id pubmed-6907163
institution National Center for Biotechnology Information
language English
publishDate 2018
record_format MEDLINE/PubMed
spelling pubmed-69071632019-12-12 Reduction in oral mucositis severity using a topical vasoconstrictor: A case report of three bone marrow transplant patients Graul-Conroy, Amanda Hoover-Regan, Margo DeSantes, Kenneth B Sondel, Paul M Callander, Natalie S Longo, Walter L Fahl, William E Integr Cancer Sci Ther Article BACKGROUND: Grade 3 oral mucositis (OM) is historically observed in >90% of bone marrow transplant patients who received the cyclophosphamide + total body irradiation (CY+TBI) conditioning regimen. It was previously shown that orotopically applied adrenergic vasoconstrictor prevented up to 100% of radiation-induced oral mucositis in two preclinical animal models. METHODS: Adrenergic vasoconstrictor (i.e., phenylephrine in an aqueous-alcohol NG11–1 formulation) was orotopically applied to three patients (ages 24–29) who received the CY+TBI conditioning regimen; they were compared to five matched controls who received no orotopical vasoconstrictor. All patients received the CY+TBI conditioning regimen for acute lymphoblastic leukemia within the University of Wisconsin Adult Bone Marrow Transplant Program. Over the seven-day Cy+TBI conditioning regimen, 20 min before each treatment, either radiation or chemotherapy, vasoconstrictor was applied topically to the oral cavity, and patients then received either 1.5 Gy whole-body radiation or IV cyclophosphamide. RESULTS: OM severity was scored over a three-week period using: i) physican assessments, ii) daily photos of the oral cavity, iii) oral pain and oral function score sheets, and iv) recorded narcotic consumption. Both “Grade 3 OM” duration and “any OM” duration in vasoconstrictor-treated patients were substantially lower than for the five control patients. Though nasogastric tube or total parenteral nutrition were used in 3 out of 5 control patients, there was no use of these supportive care measures in the three vasoconstrictor-treated patients. CONCLUSION: Orotopically applied NG11–1 vasoconstrictor formulation substantially reduced the incidence and severity of “Grade 3” and “any” oral mucositis when compared to matched control patients, all of whom received the same CY+TBI conditioning regimen. The liquid orotopical formulation was easily tolerated by patients both in its ease of use and lack of side effects. 2018-11-29 2018-12 /pmc/articles/PMC6907163/ /pubmed/31832233 http://dx.doi.org/10.15761/ICST.1000293 Text en http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Article
Graul-Conroy, Amanda
Hoover-Regan, Margo
DeSantes, Kenneth B
Sondel, Paul M
Callander, Natalie S
Longo, Walter L
Fahl, William E
Reduction in oral mucositis severity using a topical vasoconstrictor: A case report of three bone marrow transplant patients
title Reduction in oral mucositis severity using a topical vasoconstrictor: A case report of three bone marrow transplant patients
title_full Reduction in oral mucositis severity using a topical vasoconstrictor: A case report of three bone marrow transplant patients
title_fullStr Reduction in oral mucositis severity using a topical vasoconstrictor: A case report of three bone marrow transplant patients
title_full_unstemmed Reduction in oral mucositis severity using a topical vasoconstrictor: A case report of three bone marrow transplant patients
title_short Reduction in oral mucositis severity using a topical vasoconstrictor: A case report of three bone marrow transplant patients
title_sort reduction in oral mucositis severity using a topical vasoconstrictor: a case report of three bone marrow transplant patients
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6907163/
https://www.ncbi.nlm.nih.gov/pubmed/31832233
http://dx.doi.org/10.15761/ICST.1000293
work_keys_str_mv AT graulconroyamanda reductioninoralmucositisseverityusingatopicalvasoconstrictoracasereportofthreebonemarrowtransplantpatients
AT hooverreganmargo reductioninoralmucositisseverityusingatopicalvasoconstrictoracasereportofthreebonemarrowtransplantpatients
AT desanteskennethb reductioninoralmucositisseverityusingatopicalvasoconstrictoracasereportofthreebonemarrowtransplantpatients
AT sondelpaulm reductioninoralmucositisseverityusingatopicalvasoconstrictoracasereportofthreebonemarrowtransplantpatients
AT callandernatalies reductioninoralmucositisseverityusingatopicalvasoconstrictoracasereportofthreebonemarrowtransplantpatients
AT longowalterl reductioninoralmucositisseverityusingatopicalvasoconstrictoracasereportofthreebonemarrowtransplantpatients
AT fahlwilliame reductioninoralmucositisseverityusingatopicalvasoconstrictoracasereportofthreebonemarrowtransplantpatients